Llewellyn Mills

709 total citations
37 papers, 422 citations indexed

About

Llewellyn Mills is a scholar working on Pharmacology, Epidemiology and Clinical Psychology. According to data from OpenAlex, Llewellyn Mills has authored 37 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pharmacology, 19 papers in Epidemiology and 11 papers in Clinical Psychology. Recurrent topics in Llewellyn Mills's work include Substance Abuse Treatment and Outcomes (19 papers), Cannabis and Cannabinoid Research (15 papers) and Prenatal Substance Exposure Effects (6 papers). Llewellyn Mills is often cited by papers focused on Substance Abuse Treatment and Outcomes (19 papers), Cannabis and Cannabinoid Research (15 papers) and Prenatal Substance Exposure Effects (6 papers). Llewellyn Mills collaborates with scholars based in Australia, United States and France. Llewellyn Mills's co-authors include Nicholas Lintzeris, Iain S. McGregor, Jonathon C. Arnold, Anastasia Suraev, Thomas R. Arkell, Ben Colagiuri, Adrian Dunlop, Raimondo Bruno, María Fe Bravo‐Ortiz and Melissa J. Benson and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Llewellyn Mills

32 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Llewellyn Mills Australia 10 296 137 82 69 66 37 422
Sam Craft United Kingdom 8 357 1.2× 130 0.9× 78 1.0× 93 1.3× 65 1.0× 19 473
Gonzalo Rivas Australia 6 230 0.8× 136 1.0× 59 0.7× 53 0.8× 60 0.9× 9 383
Mark Montebello Australia 10 386 1.3× 163 1.2× 84 1.0× 73 1.1× 43 0.7× 34 574
Jack Wilson Australia 10 468 1.6× 158 1.2× 110 1.3× 112 1.6× 67 1.0× 23 657
Ofir Livne United States 15 362 1.2× 223 1.6× 160 2.0× 89 1.3× 104 1.6× 46 559
Debasish Basu India 14 144 0.5× 146 1.1× 97 1.2× 30 0.4× 69 1.0× 41 466
Craig Sadler Australia 8 230 0.8× 93 0.7× 45 0.5× 46 0.7× 21 0.3× 11 330
Christopher J. Hammond United States 9 169 0.6× 104 0.8× 101 1.2× 68 1.0× 59 0.9× 40 328
Stephanie Yarnell United States 8 169 0.6× 94 0.7× 82 1.0× 44 0.6× 47 0.7× 12 365
Ravi K. Das United Kingdom 6 426 1.4× 123 0.9× 88 1.1× 75 1.1× 44 0.7× 8 469

Countries citing papers authored by Llewellyn Mills

Since Specialization
Citations

This map shows the geographic impact of Llewellyn Mills's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Llewellyn Mills with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Llewellyn Mills more than expected).

Fields of papers citing papers by Llewellyn Mills

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Llewellyn Mills. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Llewellyn Mills. The network helps show where Llewellyn Mills may publish in the future.

Co-authorship network of co-authors of Llewellyn Mills

This figure shows the co-authorship network connecting the top 25 collaborators of Llewellyn Mills. A scholar is included among the top collaborators of Llewellyn Mills based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Llewellyn Mills. Llewellyn Mills is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mills, Llewellyn, et al.. (2025). Clinicians' Perspectives on Cannabis Use and Cannabis Treatment in Clients Undertaking Opioid Dependence Treatment. Drug and Alcohol Review. 44(5). 1339–1350.
2.
Mills, Llewellyn, et al.. (2025). Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series. Drug and Alcohol Dependence Reports. 15. 100329–100329. 1 indexed citations
3.
Black, Eleanor, Emma Black, Apo Demirkol, et al.. (2024). Sociodemographic and Health Factors of the Alcohol Treatment-seeking Population in New South Wales, Australia. Journal of Addiction Medicine. 18(6). 619–627.
4.
Arkell, Thomas R., Sarah V. Abelev, Llewellyn Mills, et al.. (2023). Driving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 survey. SHILAP Revista de lepidopterología. 5(1). 35–35. 4 indexed citations
5.
Mills, Llewellyn, Jessica C. Lee, Robert A. Boakes, & Ben Colagiuri. (2023). Reduction in caffeine withdrawal after open-label decaffeinated coffee. Journal of Psychopharmacology. 37(2). 181–191. 6 indexed citations
6.
Shakeshaft, Anthony, et al.. (2023). Trajectories of Psychological Distress of Men Treated at Aboriginal Residential Rehabilitation Services for Alcohol and Drug Misuse. International Journal of Mental Health and Addiction. 23(3). 2070–2088. 2 indexed citations
7.
Mills, Llewellyn, et al.. (2023). A systematic review on the effect of routine outcome monitoring and feedback on client outcomes in alcohol and other drug treatment. Drug and Alcohol Review. 42(7). 1701–1722. 4 indexed citations
8.
Suraev, Anastasia, Llewellyn Mills, Sarah V. Abelev, et al.. (2023). Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey. Nature and Science of Sleep. Volume 15. 245–255. 5 indexed citations
9.
Black, Emma, Rachel Deacon, Nadine Ezard, et al.. (2022). Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019. Drug and Alcohol Review. 42(2). 389–400. 2 indexed citations
10.
Baldwin, Peter, Melissa Black, Jill M. Newby, et al.. (2022). The Essential Network (TEN): Protocol for an Implementation Study of a Digital-First Mental Health Solution for Australian Health Care Workers During COVID-19. JMIR Research Protocols. 11(3). e34601–e34601. 2 indexed citations
11.
Monds, Lauren A., María Carmen Bravo, Llewellyn Mills, et al.. (2022). The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptions. Drug and Alcohol Review. 41(5). 1085–1094.
12.
Mills, Llewellyn, et al.. (2022). Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. Drug and Alcohol Review. 41(5). 1095–1108. 18 indexed citations
13.
Trevena, Lyndal, Bettina Meiser, Llewellyn Mills, et al.. (2022). Which Test Is Best? A Cluster-Randomized Controlled Trial of a Risk Calculator and Recommendations on Colorectal Cancer Screening Behaviour in General Practice. Public Health Genomics. 25(5-6). 193–208.
14.
Lintzeris, Nicholas, et al.. (2021). Opioid agonist treatment and patient outcomes during the COVID‐19 pandemic in south east Sydney, Australia. Drug and Alcohol Review. 41(5). 1009–1019. 28 indexed citations
15.
Mills, Llewellyn, Rachel Deacon, Raimondo Bruno, et al.. (2021). Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions. Drug and Alcohol Review. 41(1). 106–113. 6 indexed citations
16.
Deacon, Rachel, Jennifer Holmes, Adrian Dunlop, et al.. (2020). Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations. Drug and Alcohol Review. 39(5). 441–446. 15 indexed citations
17.
Mills, Llewellyn, Nicholas Lintzeris, Raimondo Bruno, et al.. (2020). Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. Drug and Alcohol Review. 39(4). 356–364. 8 indexed citations
18.
Lintzeris, Nicholas, Llewellyn Mills, Adrian Dunlop, et al.. (2020). Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug and Alcohol Dependence. 215. 108220–108220. 25 indexed citations
19.
Lintzeris, Nicholas, Llewellyn Mills, Anastasia Suraev, et al.. (2020). Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduction Journal. 17(1). 37–37. 82 indexed citations
20.
Mills, Llewellyn, Robert A. Boakes, & Ben Colagiuri. (2018). The effect of dose expectancies on caffeine withdrawal symptoms during tapered dose reduction. Journal of Psychopharmacology. 33(8). 994–1002. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sam Craft Breakdown of academic impact, for papers by Gonzalo Rivas Breakdown of academic impact, for papers by Mark Montebello Breakdown of academic impact, for papers by Jack Wilson Breakdown of academic impact, for papers by Ofir Livne Breakdown of academic impact, for papers by Debasish Basu Breakdown of academic impact, for papers by Craig Sadler Breakdown of academic impact, for papers by Christopher J. Hammond Breakdown of academic impact, for papers by Stephanie Yarnell Breakdown of academic impact, for papers by Ravi K. Das
Rankless by CCL
2026